217 related articles for article (PubMed ID: 19718049)
1. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
Seckinger A; Meissner T; Moreaux J; Goldschmidt H; Fuhler GM; Benner A; Hundemer M; Rème T; Shaughnessy JD; Barlogie B; Bertsch U; Hillengass J; Ho AD; Pantesco V; Jauch A; De Vos J; Rossi JF; Möhler T; Klein B; Hose D
Oncogene; 2009 Nov; 28(44):3866-79. PubMed ID: 19718049
[TBL] [Abstract][Full Text] [Related]
2. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes.
Grcević D; Kusec R; Kovacić N; Lukić A; Lukić IK; Ivcević S; Nemet D; Seiwerth RS; Ostojić SK; Croucher PI; Marusić A
Leuk Res; 2010 Jun; 34(6):742-51. PubMed ID: 19926132
[TBL] [Abstract][Full Text] [Related]
5. Induction of angiogenesis by normal and malignant plasma cells.
Hose D; Moreaux J; Meissner T; Seckinger A; Goldschmidt H; Benner A; Mahtouk K; Hillengass J; Rème T; De Vos J; Hundemer M; Condomines M; Bertsch U; Rossi JF; Jauch A; Klein B; Möhler T
Blood; 2009 Jul; 114(1):128-43. PubMed ID: 19299335
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
7. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
8. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
[TBL] [Abstract][Full Text] [Related]
9. CD200 is a new prognostic factor in multiple myeloma.
Moreaux J; Hose D; Reme T; Jourdan E; Hundemer M; Legouffe E; Moine P; Bourin P; Moos M; Corre J; Möhler T; De Vos J; Rossi JF; Goldschmidt H; Klein B
Blood; 2006 Dec; 108(13):4194-7. PubMed ID: 16946299
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic role of annexin A2 in multiple myeloma.
Seckinger A; Meissner T; Moreaux J; Depeweg D; Hillengass J; Hose K; Rème T; Rösen-Wolff A; Jauch A; Schnettler R; Ewerbeck V; Goldschmidt H; Klein B; Hose D
Blood; 2012 Aug; 120(5):1087-94. PubMed ID: 22705595
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
Hose D; Rème T; Meissner T; Moreaux J; Seckinger A; Lewis J; Benes V; Benner A; Hundemer M; Hielscher T; Shaughnessy JD; Barlogie B; Neben K; Krämer A; Hillengass J; Bertsch U; Jauch A; De Vos J; Rossi JF; Möhler T; Blake J; Zimmermann J; Klein B; Goldschmidt H
Blood; 2009 Apr; 113(18):4331-40. PubMed ID: 19171872
[TBL] [Abstract][Full Text] [Related]
12. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis.
Giuliani N; Colla S; Lazzaretti M; Sala R; Roti G; Mancini C; Bonomini S; Lunghi P; Hojden M; Genestreti G; Svaldi M; Coser P; Fattori PP; Sammarelli G; Gazzola GC; Bataille R; Almici C; Caramatti C; Mangoni L; Rizzoli V
Blood; 2003 Jul; 102(2):638-45. PubMed ID: 12649156
[TBL] [Abstract][Full Text] [Related]
13. miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression.
Seckinger A; Meißner T; Moreaux J; Benes V; Hillengass J; Castoldi M; Zimmermann J; Ho AD; Jauch A; Goldschmidt H; Klein B; Hose D
Oncotarget; 2015 Nov; 6(36):39165-83. PubMed ID: 26472281
[TBL] [Abstract][Full Text] [Related]
14. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
16. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.
Mahtouk K; Moreaux J; Hose D; Rème T; Meissner T; Jourdan M; Rossi JF; Pals ST; Goldschmidt H; Klein B
BMC Cancer; 2010 May; 10():198. PubMed ID: 20465808
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
18. The role of bone morphogenetic proteins in myeloma cell survival.
Holien T; Sundan A
Cytokine Growth Factor Rev; 2014 Jun; 25(3):343-50. PubMed ID: 24853340
[TBL] [Abstract][Full Text] [Related]
19. CD138
Wu D; Zhang P; Li F; Shen Y; Chen H; Feng Y; He A; Wang F
Aging (Albany NY); 2020 Nov; 12(22):23067-23081. PubMed ID: 33197893
[TBL] [Abstract][Full Text] [Related]
20. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
